10-Q: Skinvisible, Inc. Reports Flat Revenue in Q1 2025, Continues Focus on Licensing and Transdermal Delivery

Skinvisible, Inc. reports consistent revenue of $5,000 for Q1 2025, maintaining its focus on licensing agreements and exploring transdermal delivery applications.

Summary

• Skinvisible, Inc. reported its financial results for the quarter ended March 31, 2025.
• Revenue remained consistent at $5,000 compared to the same period in 2024.
• The company experienced a net loss of $281,005, slightly improved from the $290,372 loss in Q1 2024.
• Operating expenses increased to $144,852 from $128,184 year-over-year.
• The company is focusing on licensing its Invisicare technology and exploring new opportunities in transdermal delivery for obesity and glucose control.
• Skinvisible has a working capital deficit of $4,218,598 as of March 31, 2025.
• The company acknowledges substantial doubt about its ability to continue as a going concern without additional funding.
• Management plans to generate funding through licensing and seek additional debt and equity financing.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to flat revenue, continued losses, increasing operating expenses, a significant working capital deficit, and doubts about the company's ability to continue as a going concern. However, there are some positive developments with Quoin's clinical trials and the exploration of new applications for the company's technology.

Positives

• Net loss decreased slightly compared to the same period last year.
• Quoin Pharmaceuticals is making progress in clinical trials for QRX003, which utilizes Skinvisible's Invisicare technology.
• The company is actively pursuing licensing agreements and exploring new applications for its technology.
• The company has filed provisional patent applications for transdermal delivery of obesity drugs and glucose-controlling agents.

Negatives

• Revenue remained flat year-over-year.
• The company continues to operate at a net loss.
• Operating expenses increased.
• The company has a significant working capital deficit.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company acknowledges material weaknesses in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain without additional funding.
• The company faces risks related to obtaining adequate financing on a timely basis and on acceptable terms.
• The company's success depends on the successful development and commercialization of its technologies and products.
• The company faces competition from other companies in the skincare and dermatology markets.
• The company acknowledges material weaknesses in internal control over financial reporting.

Future Outlook

The company hopes to generate more revenues from its licenses with Quoin and Ovation in 2025 and plans to enter into commercial arrangements with pharma and biotech companies to exploit its patent applications that were recently filed.

Management Comments

• Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding.
• The opportunity for us to license our products continues to be a viable model as the need for pharmaceutical companies to access external R&D companies for new products due to their own downsizing or elimination of internal R&D departments.

Industry Context

The company targets an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market, as well as other healthcare/medical and consumer goods markets.

Comparison to Industry Standards

• It's difficult to directly compare Skinvisible to industry giants like Johnson & Johnson or Novartis due to its size and business model.
• However, the focus on licensing and transdermal delivery aligns with industry trends towards specialized drug delivery systems, similar to companies like Durect Corporation.
• Quoin Pharmaceuticals' progress with QRX003 is a positive sign, but the success of clinical trials is crucial for future revenue generation, similar to the challenges faced by other biotech companies like BioCryst Pharmaceuticals.

Related Party Transactions

• On January 31, 2023, the Company negotiated accrued salaries, vacation, and outstanding convertible notes for its two officers.

Stakeholder Impact

• Shareholders face the risk of dilution if the company issues additional shares to raise capital.
• Employees face uncertainty due to the company's financial difficulties and doubts about its ability to continue as a going concern.
• Customers may be impacted if the company is unable to continue developing and commercializing its products.
• Creditors face the risk of non-payment if the company is unable to generate sufficient revenue or raise additional capital.

Next Steps

• The company plans to continue pursuing licensing agreements for its Invisicare technology.
• The company plans to continue exploring new opportunities in transdermal delivery for obesity and glucose control.
• The company plans to seek additional financing through debt and/or equity financing arrangements.

Key Dates

Keywords

Skinvisible, Invisicare, licensing, transdermal delivery, Netherton Syndrome, Quoin Pharmaceuticals, Ovation Science, financial results, patent applications, pharmaceutical, skincare, dermatology